Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Outcomes of patients with severely calcified aorto‐ostial coronary lesions who underwent orbital atherectomy

View through CrossRef
ObjectivesWe assessed the feasibility and safety of orbital atherectomy in patients with severely calcified aorto‐ostial coronary artery lesions.BackgroundThe treatment of calcified aorta‐ostial coronary artery lesions is technically challenging. Orbital atherectomy can potentially damage the guiding catheter if it is not retracted sufficiently during treatment of ostial lesions. Orbital atherectomy can also excessively whip if the guiding catheter is not close enough to the ostium to provide sufficient support. Several techniques can be performed to successfully treat ostial lesions with orbital atherectomy.MethodsOur retrospective multicenter registry included 548 real‐world patients who underwent orbital atherectomy, 59 (10.8%) of whom underwent treatment for aorto‐ostial coronary artery lesions (left main artery [n = 35] and right coronary artery [n = 24]). The primary endpoint was the rate of 30‐day major adverse cardiac and cerebrovascular events (MACCE), defined as the occurrence of death, myocardial infarction, target vessel revascularization, and stroke.ResultsThe primary endpoint was similar in patients with and without ostial lesions (3.4% vs 2.2%, P = 0.2), as were the 30‐day rates of death (1.7% vs 1.4%, P = 0.7), myocardial infarction (1.7% vs 1.0%, P = 0.3), target vessel revascularization (0% vs 0%, P > 0.91), and stroke (0% vs 0.2%, P > 0.9). Angiographic complications and stent thrombosis did not occur in patients with ostial lesions.ConclusionsDespite its technical challenges, orbital atherectomy appears to be a feasible and safe treatment option for calcified aorto‐ostial coronary lesions.
Title: Outcomes of patients with severely calcified aorto‐ostial coronary lesions who underwent orbital atherectomy
Description:
ObjectivesWe assessed the feasibility and safety of orbital atherectomy in patients with severely calcified aorto‐ostial coronary artery lesions.
BackgroundThe treatment of calcified aorta‐ostial coronary artery lesions is technically challenging.
Orbital atherectomy can potentially damage the guiding catheter if it is not retracted sufficiently during treatment of ostial lesions.
Orbital atherectomy can also excessively whip if the guiding catheter is not close enough to the ostium to provide sufficient support.
Several techniques can be performed to successfully treat ostial lesions with orbital atherectomy.
MethodsOur retrospective multicenter registry included 548 real‐world patients who underwent orbital atherectomy, 59 (10.
8%) of whom underwent treatment for aorto‐ostial coronary artery lesions (left main artery [n = 35] and right coronary artery [n = 24]).
The primary endpoint was the rate of 30‐day major adverse cardiac and cerebrovascular events (MACCE), defined as the occurrence of death, myocardial infarction, target vessel revascularization, and stroke.
ResultsThe primary endpoint was similar in patients with and without ostial lesions (3.
4% vs 2.
2%, P = 0.
2), as were the 30‐day rates of death (1.
7% vs 1.
4%, P = 0.
7), myocardial infarction (1.
7% vs 1.
0%, P = 0.
3), target vessel revascularization (0% vs 0%, P > 0.
91), and stroke (0% vs 0.
2%, P > 0.
9).
Angiographic complications and stent thrombosis did not occur in patients with ostial lesions.
ConclusionsDespite its technical challenges, orbital atherectomy appears to be a feasible and safe treatment option for calcified aorto‐ostial coronary lesions.

Related Results

Outcomes in Diabetic Patients Undergoing Orbital Atherectomy System
Outcomes in Diabetic Patients Undergoing Orbital Atherectomy System
ObjectivesWe evaluated the angiographic and clinical outcomes of orbital atherectomy to treat severely calcified coronary lesions in diabetic and non‐diabetic patients.BackgroundDi...
Hydatid Cyst of The Orbit: A Systematic Review with Meta-Data
Hydatid Cyst of The Orbit: A Systematic Review with Meta-Data
Abstarct Introduction Orbital hydatid cysts (HCs) constitute less than 1% of all cases of hydatidosis, yet their occurrence is often linked to severe visual complications. This stu...
Ostial Lesions of Left Main and Right Coronary Arteries: Demographic and Angiographic Features
Ostial Lesions of Left Main and Right Coronary Arteries: Demographic and Angiographic Features
In 258 patients with left main tract disease, the atherosclerotic risk factors were compared between patients with ostial and nonostial lesions of the left main coronary artery. Al...
Outcomes in Elderly Patients With Severely Calcified Coronary Lesions Undergoing Orbital Atherectomy
Outcomes in Elderly Patients With Severely Calcified Coronary Lesions Undergoing Orbital Atherectomy
ObjectivesWe evaluated the clinical outcomes of elderly patients who underwent orbital atherectomy for the treatment of severe coronary artery calcification (CAC) prior to stenting...
Cutting Balloon Angioplasty and Stent Implantation for Aorto‐ostial Lesions: Clinical Outcome and 1‐year Follow‐up
Cutting Balloon Angioplasty and Stent Implantation for Aorto‐ostial Lesions: Clinical Outcome and 1‐year Follow‐up
AbstractBackgroundPercutaneous interventions for aorto‐ostial narrowing of native coronary arteries are challenging because of early elastic recoil after the procedure and the high...
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Abstract Introduction Coronary subclavian steal syndrome (CSSS) is a rare phenomenon that often goes undiagnosed and causes severe complications, including death. This report prese...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top